Henrik Horndalsveen

Oslo, Norway

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Gut microbiota alterations in patients with non-small-cell lung cancer undergoing chemoradiotherapy.

Gut microbiota alterations in patients with non-small-cell lung cancer undergoing chemoradiotherapy.

Journal: Molecular oncology

Published: March 23, 2026

ctDNA based MRD detection in stage III NSCLC treated with chemoradiotherapy and durvalumab.

ctDNA based MRD detection in stage III NSCLC treated with chemoradiotherapy and durvalumab.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: January 03, 2026

How does pulmonary function impact QoL in patients with locally advanced NSCLC treated with chemoradiotherapy and durvalumab?

How does pulmonary function impact QoL in patients with locally advanced NSCLC treated with chemoradiotherapy and durvalumab?

Journal: Acta oncologica (Stockholm, Sweden)

Published: November 12, 2025

Upfront treatment with osimertinib in lung cancer patients with and without active brain metastases, and the role of ctDNA as a biomarker; a phase II clinical trial (the FIOL study).

Upfront treatment with osimertinib in lung cancer patients with and without active brain metastases, and the role of ctDNA as a biomarker; a phase II clinical trial (the FIOL study).

Journal: Lung cancer (Amsterdam, Netherlands)

Published: November 10, 2025

Blood-based tumor mutational burden as a biomarker in unresectable non-small cell lung cancer treated with chemoradiotherapy and durvalumab.

Blood-based tumor mutational burden as a biomarker in unresectable non-small cell lung cancer treated with chemoradiotherapy and durvalumab.

Journal: Frontiers in oncology

Published: August 07, 2025

Serum cytokines as a biomarker for immune checkpoint inhibitor toxicity in patients with pleural mesothelioma.

Serum cytokines as a biomarker for immune checkpoint inhibitor toxicity in patients with pleural mesothelioma.

Journal: Frontiers in immunology

Published: August 13, 2024

Thoracic radiation in combination with erlotinib-results from a phase 2 randomized trial.

Thoracic radiation in combination with erlotinib-results from a phase 2 randomized trial.

Journal: Frontiers in oncology

Published: April 05, 2024

Factors associated with failure to start consolidation durvalumab after definitive chemoradiation for locally advanced NSCLC.

Factors associated with failure to start consolidation durvalumab after definitive chemoradiation for locally advanced NSCLC.

Journal: Frontiers in oncology

Published: May 05, 2023

Checkpoint inhibitor-induced myocarditis

Checkpoint inhibitor-induced myocarditis

Journal: Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke

Published: December 13, 2022

Atezolizumab and stereotactic body radiotherapy in patients with advanced non-small cell lung cancer: safety, clinical activity and ctDNA responses-the ComIT-1 trial.

Atezolizumab and stereotactic body radiotherapy in patients with advanced non-small cell lung cancer: safety, clinical activity and ctDNA responses-the ComIT-1 trial.

Journal: Molecular oncology

Published: May 20, 2022

NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma.

NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma.

Journal: Journal of translational medicine

Published: April 10, 2021

Cancer patient in his 50's with troublesome palpitations

Cancer patient in his 50's with troublesome palpitations

Journal: Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke

Published: September 06, 2017

Showing 1-12 of 12

Last Updated: 09/26/2026